Effect of mass dihydroartemisinin-piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
06
2020
accepted:
21
09
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Mass drug administration (MDA) can rapidly reduce the burden of Plasmodium falciparum (Pf). However, concerns remain about its contribution to select for antimalarial drug resistance. We used Sanger sequencing and real-time PCR to determine the proportion of molecular markers associated with antimalarial resistance (k13, pfpm2, pfmdr1 and pfcrt) in Pf isolates collected before (n = 99) and after (n = 112) the implementation of two monthly MDA rounds with dihydroartemisinin-piperaquine (DHAp) for two consecutive years in Magude district of Southern Mozambique. None of the k13 polymorphisms associated with artemisinin resistance were observed in the Pf isolates analyzed. The proportion of Pf isolates with multiple copies of pfpm2, an amplification associated with piperaquine resistance, was similar in pre- (4.9%) and post-MDA groups (3.4%; p = 1.000). No statistically significant differences were observed between pre- and post-MDA groups in the proportion of Pf isolates neither with mutations in pfcrt and pfmdr1 genes, nor with the carriage of pfmdr1 multiple copies (p>0.05). This study does not show any evidence of increased frequency of molecular makers of antimalarial resistance after MDA with DHAp in southern Mozambique where markers of antimalarial resistance were absent or low at the beginning of the intervention.
Sections du résumé
BACKGROUND
Mass drug administration (MDA) can rapidly reduce the burden of Plasmodium falciparum (Pf). However, concerns remain about its contribution to select for antimalarial drug resistance.
METHODS
We used Sanger sequencing and real-time PCR to determine the proportion of molecular markers associated with antimalarial resistance (k13, pfpm2, pfmdr1 and pfcrt) in Pf isolates collected before (n = 99) and after (n = 112) the implementation of two monthly MDA rounds with dihydroartemisinin-piperaquine (DHAp) for two consecutive years in Magude district of Southern Mozambique.
RESULTS
None of the k13 polymorphisms associated with artemisinin resistance were observed in the Pf isolates analyzed. The proportion of Pf isolates with multiple copies of pfpm2, an amplification associated with piperaquine resistance, was similar in pre- (4.9%) and post-MDA groups (3.4%; p = 1.000). No statistically significant differences were observed between pre- and post-MDA groups in the proportion of Pf isolates neither with mutations in pfcrt and pfmdr1 genes, nor with the carriage of pfmdr1 multiple copies (p>0.05).
CONCLUSIONS
This study does not show any evidence of increased frequency of molecular makers of antimalarial resistance after MDA with DHAp in southern Mozambique where markers of antimalarial resistance were absent or low at the beginning of the intervention.
Identifiants
pubmed: 33075062
doi: 10.1371/journal.pone.0240174
pii: PONE-D-20-19842
pmc: PMC7571678
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Drug Combinations
0
Protozoan Proteins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0240174Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
PLoS Med. 2020 Aug 21;17(8):e1003214
pubmed: 32822362
J Trop Med. 2015;2015:917370
pubmed: 26557143
Clin Infect Dis. 2018 Nov 13;67(11):1670-1676
pubmed: 29846536
Am J Trop Med Hyg. 2020 Aug;103(2_Suppl):7-18
pubmed: 32618247
PLoS Med. 2019 Feb 15;16(2):e1002745
pubmed: 30768615
Science. 2016 Apr 15;352(6283):349-53
pubmed: 27081071
Malar J. 2016 Mar 31;15:185
pubmed: 27036739
Cochrane Database Syst Rev. 2013 Dec 09;(12):CD008846
pubmed: 24318836
Trends Parasitol. 2003 Oct;19(10):452-60
pubmed: 14519583
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Am J Trop Med Hyg. 2015 Jul;93(1):125-134
pubmed: 26013371
PLoS One. 2016 Nov 21;11(11):e0166699
pubmed: 27870874
Malar J. 2009 Jan 09;8:9
pubmed: 19134201
Nat Commun. 2016 May 18;7:11553
pubmed: 27189525
Infect Drug Resist. 2018 Mar 01;11:299-306
pubmed: 29535546
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Antimicrob Agents Chemother. 2014 Jul;58(7):3660-5
pubmed: 24733476
Malar J. 2018 Nov 3;17(1):405
pubmed: 30390647
mBio. 2017 May 9;8(3):
pubmed: 28487425
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130434
pubmed: 24821920
J Infect Dis. 2016 Dec 15;214(12):1831-1839
pubmed: 27923947
Emerg Infect Dis. 2017 Apr;23(4):715-717
pubmed: 28322709
Lancet. 2018 Apr 21;391(10130):1599-1607
pubmed: 29428183
J Clin Microbiol. 2014 Jun;52(6):2144-9
pubmed: 24740073
Lancet Infect Dis. 2019 Jan;19(1):e14-e25
pubmed: 30292480
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26
pubmed: 26014949
Lancet Infect Dis. 2017 Jan;17(1):e15-e20
pubmed: 27839929
Lancet Infect Dis. 2020 Jul 14;:
pubmed: 32679084
Nat Ecol Evol. 2018 Feb;2(2):377-387
pubmed: 29255304
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Nature. 2019 Dec;576(7786):315-320
pubmed: 31776516
Mol Biol Evol. 2000 Oct;17(10):1467-82
pubmed: 11018154
Clin Infect Dis. 2016 Sep 15;63(6):784-791
pubmed: 27313266
Parasitology. 2006 Nov;133(Pt 5):589-601
pubmed: 16834821
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
Antimicrob Agents Chemother. 2015 Aug;59(8):4387-96
pubmed: 25918149
Emerg Infect Dis. 2017 Jan;24(1):40-48
pubmed: 29260689
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Malar J. 2014 Sep 24;13:380
pubmed: 25249272
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Lancet. 2018 May 12;391(10133):1916-1926
pubmed: 29703425
N Engl J Med. 2015 Oct 22;373(17):1607-17
pubmed: 26488692
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
BMC Med. 2019 Jan 17;17(1):1
pubmed: 30651111
Lancet. 2000 Nov 4;356(9241):1560-4
pubmed: 11075770
PLoS Med. 2020 Aug 14;17(8):e1003227
pubmed: 32797101
J Infect Dis. 2014 Jul 1;210(1):65-71
pubmed: 24446528
J Infect Dis. 2006 Aug 15;194(4):528-35
pubmed: 16845638
Malar J. 2018 Aug 2;17(1):279
pubmed: 30071877
Wellcome Open Res. 2017 Sep 6;2:81
pubmed: 29062913